Patient‐derived organoids are being considered as models that can help guide
personalized therapy through in vitro anticancer drug response evaluation. However …

Simple Summary Colorectal cancer (CRC) is the third most common type of cancer globally.
Despite successful treatment, it has a 40% chance of recurrence within five years after …

There is a clear and unmet clinical need for biomarkers to predict responsiveness to
chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor …

Introduction: Most advanced colorectal cancers are aggressive, and there is a lack of
effective methods for selecting appropriate anticancer regimens. Patient-derived organoids …

While chemotherapy alone or in combination with radiotherapy and surgery are important
modalities in the treatment of colorectal cancer, their widespread use is not paired with an …

Simple Summary Colorectal cancer is the third most commonly diagnosed cancer. Patients
may receive chemotherapy, targeted therapy, immunotherapy, radiotherapy, and/or surgery …

Colorectal cancer is one of the most important malignancies worldwide, with high incidence
and mortality rates. Several studies have been conducted using two-dimensional cultured …

Currently, colorectal cancer is still the third leading cause of cancer-related mortality, and the
incidence is rising. It is a long time since the researchers used cancer cell lines and animals …

Patient derived organoids closely resemble the biology of tissues and tumors. They are
enabling ex vivo modeling of human diseases and dissecting key features of tumor biology …

Background The prognosis of patients with different gastrointestinal cancers varies widely.
Despite advances in treatment strategies, such as extensive resections and the addition of …